through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
![Biogen logo](/files/LOGO/875045-BIIB.png)
Company profile
Ticker
BIIB
Exchange
Website
CEO
George Scangos
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
Corporate docs
Subsidiaries
Biogen Foundation Inc. • Biogen MA Inc. • Biogen Realty Corporation • Biogen Realty Limited Partnership • Biogen U.S. Corporation • Biogen U.S. Limited Partnership • Biogen (RTP) Realty LLC • Biogen Chesapeake LLC • Biogen Digital Health Inc. • Biogen Digital Health Global LLC ...
IRS number
330112644
BIIB stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
25 Jun 24
S-8
Registration of securities for employees
20 Jun 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-Q
2024 Q1
Quarterly report
24 Apr 24
8-K
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
24 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
13 Feb 24
Transcripts
BIIB
Earnings call transcript
2024 Q1
24 Apr 24
BIIB
Earnings call transcript
2023 Q4
13 Feb 24
BIIB
Earnings call transcript
2023 Q3
8 Nov 23
BIIB
Earnings call transcript
2023 Q2
25 Jul 23
BIIB
Earnings call transcript
2023 Q1
25 Apr 23
BIIB
Earnings call transcript
2022 Q4
15 Feb 23
BIIB
Earnings call transcript
2022 Q3
25 Oct 22
BIIB
Earnings call transcript
2022 Q2
20 Jul 22
BIIB
Earnings call transcript
2022 Q1
3 May 22
BIIB
Earnings call transcript
2021 Q4
3 Feb 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.07 bn | 1.07 bn | 1.07 bn | 1.07 bn | 1.07 bn | 1.07 bn |
Cash burn (monthly) | (no burn) | 151.98 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 587.66 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 486.74 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 3.2 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
75.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 894 |
Opened positions | 231 |
Closed positions | 150 |
Increased positions | 235 |
Reduced positions | 264 |
13F shares | Current |
---|---|
Total value | 20.46 tn |
Total shares | 109.21 mm |
Total puts | 1.17 mm |
Total calls | 1.18 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 16.57 mm | $3.57 tn |
BLK Blackrock | 14.14 mm | $3.05 tn |
STT State Street | 6.75 mm | $1.45 tn |
T. Rowe Price Investment Management | 5.17 mm | $1.11 bn |
Wellington Management | 5.12 mm | $1.10 tn |
JPM JPMorgan Chase & Co. | 4.69 mm | $1.01 tn |
Geode Capital Management | 3.41 mm | $733.41 bn |
Van Eck Associates | 1.74 mm | $374.62 mm |
MS Morgan Stanley | 1.70 mm | $366.87 bn |
IVZ Invesco | 1.67 mm | $359.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jun 24 | Dorsa Caroline | Common Stock | Grant | Acquire A | No | No | 0 | 1,785 | 0.00 | 26,607 |
21 Jun 24 | Freire Maria C | Common Stock | Grant | Acquire A | No | No | 0 | 1,340 | 0.00 | 4,445 |
21 Jun 24 | Hawkins William A | Common Stock | Grant | Acquire A | No | No | 0 | 1,340 | 0.00 | 6,490 |
21 Jun 24 | Susan Langer | Common Stock | Grant | Acquire A | No | No | 0 | 1,340 | 0.00 | 2,759.1 |
21 Jun 24 | Monish D Patolawala | Common Stock | Grant | Acquire A | No | No | 0 | 1,340 | 0.00 | 1,340 |
News
Needham Reiterates Buy on Biogen, Maintains $294 Price Target
26 Jul 24
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
26 Jul 24
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
26 Jul 24
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
26 Jul 24
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
24 Jul 24
Press releases
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
26 Jul 24
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
25 Jul 24
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
24 Jul 24
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
22 Jul 24
Biogen Inc. Sued for Securities Law Violations - Contact the Schall Law Firm to Discuss Your Legal Rights BIIB
22 Jul 24